GlassScriptPhysician profile
Tiffany Moos
NPI 1427783380
$2,125.91
in general payments reported to CMS, 2019-2025
20 companies · $490 in 2025
The $490 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $838 · 2024: $798 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,125.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $452.10 | 2023-2025 | |
| Viiv Healthcare Company | $339.13 | 2023-2024 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $310.29 | 2023-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $173.08 | 2023-2025 | Pifeltro, Delstrigo, Dificid |
| Janssen Pharmaceuticals, INC | $156.92 | 2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $138.02 | 2024-2025 | Rexulti |
| Corium, LLC | $102.81 | 2023-2024 | Azstarys |
| Astellas Pharma US INC | $72.93 | 2024-2025 | Veozah |
| Antares Pharma, INC. | $59.90 | 2024-2025 | Xyosted |
| Janssen Scientific Affairs, LLC | $54.32 | 2023 | Symtuza |
| Axsome Therapeutics, INC. | $54.13 | 2024-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $51.87 | 2024-2025 | Farxiga, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.41 | 2025 | Caplyta |
| Halozyme INC | $26.99 | 2023 | |
| Organon LLC | $20.81 | 2025 | Nexplanon |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $17.69 | 2023 | Symtuza |
| Supernus Pharmaceuticals, INC. | $17.20 | 2024 | Tlando, Xyosted, Qelbree |
| Teva Pharmaceuticals USA, INC. | $16.99 | 2024 | Austedo Xr |
| Lilly USA, LLC | $16.77 | 2023 | Emgality |
| Novo Nordisk INC | $16.55 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Moos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.